13F Holdings
中文EN

NBTX Nanobiotix S.A. IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1760854 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2021-12-31 (FY2021), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY5.4%
TTM net income YoY-40.1%
TTM EPS YoY2.2%
Revenue 3-yr CAGR-8.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,986.4%
Net margin-1,778.0%
FCF margin-1,137.1%
EBITDA margin-1,927.4%

Returns

ROE-96.8%
ROA-39.9%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets73.7%
Debt / equity0.00x
Current ratio2.53x
Interest coverage-67.41x

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-14.6%
Payout ratio—
Capex / revenue8.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: EUR FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue32.59M-7.19M36.21M4.78M2.65M
R&D expense23.11M40.54M38.40M32.64M30.38M
SG&A expense20.36M20.53M22.05M17.86M19.43M
Operating income-10.82M-68.39M-26.78M-46.70M-52.58M
Interest expense15.23M7.49M14.80M13.86M780,000
Pretax income-23.96M-68.13M-39.70M-57.04M-47.00M
Income tax3,000101,000120,00010,0005,000
Net income-23.96M-68.13M-39.70M-57.04M-47.06M
EBITDA-9.32M-66.77M-25.27M-45.20M-51.02M
EPS (basic)-0.50-1.44-1.08-1.64-1.35
EPS (diluted)-0.50-1.44-1.08-1.64-1.35
Banking
Net interest income-10.27M-7.92M-7.78M-5.60M-383,000
Balance sheet
Cash & equivalents52.75M49.74M75.28M41.39M83.92M
Receivables2.14M2.98M905,000101,0000
Current assets62.75M61.47M87.34M52.36M93.06M
PP&E, netmay include right-of-use assets (IFRS)4.57M5.54M6.25M7.12M8.19M
Intangibles10,0007,0008,0001,0004,000
Total assets67.76M67.42M93.90M59.77M101.77M
Current liabilities57.51M58.94M49.87M37.94M36.84M
Total liabilities152.24M133.12M95.74M86.81M74.98M
Shareholders' equity-84.48M-65.70M-1.84M-27.05M26.79M
Cash flow statement
Operating cash flow-33.42M-19.55M-12.48M-37.10M-29.87M
Capital expenditure538,000846,000328,00092,000228,000
Free cash flow-33.96M-20.40M-12.80M-37.20M-30.10M
Investing cash flow-578,000-955,000-349,000138,000-242,000
Financing cash flow37.42M-5.13M46.77M-5.65M-5.18M
Depreciation & amortization1.50M1.62M1.51M1.50M1.56M
Stock-based compensation3.54M4.30M3.22M3.17M3.20M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.